Investigational drug · Phase 3
SFA002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Psoriasis (PsO).
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SFA002"
First trial start
2025
Jun 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SFA002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis (PsO)
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SFA002" as an intervention, largest first.
- Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis PatientsPivotal-lookingNot yet recruiting
SFA TherapeuticsIndustry
NCT06863493 · 125 participants (planned) · Start Jun 1, 2025 · Primary completion Jun 1, 2026
Drug: SFA002; Otezla and 1 more · For: Psoriasis (PsO)
SFA TherapeuticsIndustry
NCT05642182 · 90 participants (planned) · Start Mar 31, 2022 · Primary completion Jul 30, 2025
Drug: SFA002; SFA002 · For: Psoriasis
Sites: Pompano Beach, Florida; Fargo, North Dakota; Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Psoriasis (PsO)
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- HB0017Phase 21 trial
Huabo Biopharm Co., Ltd. · Psoriasis (PsO)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.